Trial Profile

A clinical trial of ICP 538 for autoimmune diseases

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 18 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ICP 538 (Primary)
Indications Autoimmune disorders; Inflammatory bowel diseases; Multiple sclerosis; Systemic lupus erythematosus
Focus Adverse reactions

Most Recent Events

18 Feb 2026 New trial record
09 Feb 2026 According to InnoCare media release, company announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to conduct clinical trials of ICP-538.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com